
AbbVie and Tentarix Partner to Innovate Conditional Multi-Specific Biologics for Oncology and Immunology
AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics have unveiled a significant collaboration aimed at pioneering the development of conditionally-active, multi-specific biologics targeting oncology and immunology. This strategic alliance will harness AbbVie’s extensive experience in these fields alongside Tentarix’s groundbreaking Tentacles™…













